<DOC>
	<DOCNO>NCT02786745</DOCNO>
	<brief_summary>To find safety effectiveness dapsone .</brief_summary>
	<brief_title>Safety Efficacy Study Dapsone Gel Patients With Acne Vulgaris</brief_title>
	<detailed_description>The purpose study find safety effectiveness investigational drug call Dapsone gel patient acne vulgaris .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Adolescent adult male female patient 12 year age old . Acne vulgaris patient minimum 20 50 inflammatory lesion face ; minimum 30 100 noninflammatory lesion . Patients acne grade 3 ( moderate ) A negative uring pregnancy test result female childbearing potential screening day 1 visit . Patient good health determine medical history , physical examination , vital sign . Patient willing avoid excessive prolonged exposure treat skin ultraviolet throughout study . Patient willing follow study instruction , complete study assessment without assistance , likely complete require visit . Uncontrolled systemic disease ( ) . Severe cystic acne , acne conglobata , acne fulminans , secondary acne . One nodule ( ) cyst ( ) mandibular line . Using systemic immunosuppressive drug within 4 week prior screen anticipate use systemic therapy potential affect acne study . Any following topical procedure treatment face occur specified period prior baseline ( day 1 ) . '' 1 week : phototherapy device , energybased device , adhesive cleanse strip , cosmetic procedure . 2 week : antiinflammatory drug , salicylic acid , coricosteroids , antibiotic , antibacterial , retinoids , topical acne treatment . Any following systemic medication take specified period prior baseline ( day 1 ) : 2 week : antiinflammatory drug 4 week : antibiotic 6 month : acne treatment Skin abnormality ( acne vulgaris ) , excessive hair , physical characteristic around test site could confound study Patients allergy sensitivity study drug component Females pregnant , nursing , plan pregnancy study think may pregnant start study Current enrollment investigational drug device study , participation study whithin 30 day prior screen study Taking oral dapsone antimalarial medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>